While the subcutaneous (SC) route of administration (RoA) is more patient‐centric and cost‐effective than the intravenous (IV) RoA, the Switch‐to‐SC paradigm has been employed in oncology antibody drug development. T cell engagers (TCEs) are typically highly potent and efficacious at low doses, supporting their suitability for the Direct‐to‐SC in FIH paradigm. This perspective discusses anticipated clinical pharmacology challenges associated with the Direct‐to‐SC in FIH paradigm and provides potential solutions to address the challenges.